[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pyxis Oncology Inc (PYXS)

Pyxis Oncology Inc (PYXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 118,122
  • Shares Outstanding, K 62,831
  • Annual Sales, $ 13,860 K
  • Annual Income, $ -79,620 K
  • EBIT $ -82 M
  • EBITDA $ -80 M
  • 60-Month Beta 1.41
  • Price/Sales 7.75
  • Price/Cash Flow N/A
  • Price/Book 1.99

Options Overview Details

View History
  • Implied Volatility 173.97% (+27.03%)
  • Historical Volatility 77.95%
  • IV Percentile 11%
  • IV Rank 14.40%
  • IV High 907.78% on 01/20/26
  • IV Low 50.57% on 09/12/25
  • Expected Move (DTE 22) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 40
  • Volume Avg (30-Day) 139
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 3,470
  • Open Int (30-Day) 4,924
  • Expected Range 1.7211 to 1.7211

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.35
  • Number of Estimates 4
  • High Estimate $-0.31
  • Low Estimate $-0.40
  • Prior Year $-0.35
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2600 +37.30%
on 03/30/26
1.9400 -10.82%
on 04/22/26
+0.3100 (+21.83%)
since 03/23/26
3-Month
1.2600 +37.30%
on 03/30/26
1.9400 -10.82%
on 04/22/26
+0.1000 (+6.13%)
since 01/23/26
52-Week
0.9700 +78.35%
on 08/11/25
5.5500 -68.83%
on 11/26/25
+0.6500 (+60.19%)
since 04/23/25

Most Recent Stories

More News
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC maMICVO monotherapy modulated the tumor-immune environment...

PYXS : 1.7200 (-8.51%)
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter...

PYXS : 1.7200 (-8.51%)
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership...

PYXS : 1.7200 (-8.51%)
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The war on cancer is moving into a high-tech era of molecular-guided defense. The genomics in cancer care...

ONCY : 1.0950 (-4.78%)
PYXS : 1.7200 (-8.51%)
PSNL : 5.83 (-7.61%)
NBP : 2.46 (-4.65%)
TOI : 3.23 (-6.10%)
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO...

PYXS : 1.7200 (-8.51%)
Pyxis Oncology to Participate in Upcoming Investor Conferences

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management...

PYXS : 1.7200 (-8.51%)
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

-  Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth...

PYXS : 1.7200 (-8.51%)
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO) MICVO combats solid tumors through three-pronged mechanism of action: direct tumor...

PYXS : 1.7200 (-8.51%)
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced...

PYXS : 1.7200 (-8.51%)
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat...

PYXS : 1.7200 (-8.51%)

Business Summary

Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 2.2333
2nd Resistance Point 2.0867
1st Resistance Point 1.9833
Last Price 1.7200
1st Support Level 1.7333
2nd Support Level 1.5867
3rd Support Level 1.4833

See More

52-Week High 5.5500
Fibonacci 61.8% 3.8004
Fibonacci 50% 3.2600
Fibonacci 38.2% 2.7196
Last Price 1.7200
52-Week Low 0.9700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.